Lc16m8: an Attenuated Smallpox Vaccine.
From: VaxGen Inc, USA. jkenner@vaxgen.com
Vaccine
- Publish Date: Nov 2006
- ISSN: 0264-410X
- Volume: 24
- Issue: 47-48
- Pages: 7009-22
- Medium: Print
- Language: English
- Citation (JAMA): Kenner Julie, Cameron Fiona, Empig Cyril, et al. Lc16m8: an Attenuated Smallpox Vaccine.. Vaccine Nov 2006;24:7009-22
Abstract
The frequency of moderate to severe adverse reactions associated with smallpox vaccines currently stockpiled in the US, and the continued threat of bioterrorism have prompted the development of effective vaccines with improved safety profiles. LC16m8, an attenuated, replicating smallpox vaccine derived from the Lister strain of vaccinia, is currently licensed in Japan where it was safely used in over 50,000 children in the 1970s. It has been shown to have markedly less neurotoxicity than unattenuated vaccines in nonclinical studies. LC16m8 is immunogenic after a single dose, and recent studies in two different animal models have demonstrated protective efficacy equivalent to that of the only FDA-licensed smallpox vaccine. This article reviews the history and available scientific literature regarding LC16m8 and provides comparisons to other smallpox vaccines.
Mesh Headings (Keywords): Animals, Bioterrorism, Genetic Vectors, Humans, Smallpox, Smallpox Vaccine, United States, United States Food and Drug Administration, Vaccines, Attenuated
Check for Full Text / PubMed Unique Identifier (PMID): 17052815
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.